GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pliant Therapeutics
Pliant Therapeutics is a biotech company developing drugs to treat fibrotic diseases. Its stock price is highly volatile and driven by news about clinical trials. The chart reflects investor hopes for a breakthrough in the treatment of these complex conditions.
Share prices of companies in the market segment - Specialized pharma
Pliant Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis. We classify it as a "Specialty Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Pliant Therapeutics is a biotech company developing drugs to treat fibrotic diseases such as pulmonary and liver fibrosis. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Pliant shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PLRX - Daily change in the company's share price Pliant Therapeutics
For Pliant Therapeutics, which develops anti-fibrosis drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Specialized pharma
For Pliant Therapeutics, which develops anti-fibrosis drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
Pliant Therapeutics is a biotech company specializing in the treatment of fibrotic diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall flow of market movements, shaping its daily pattern.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pliant Therapeutics
For Pliant Therapeutics, the year-over-year trend is a story of drug development for fibrotic diseases. Its 12-month market cap is entirely dependent on clinical trial data for its lead candidate for the treatment of idiopathic pulmonary fibrosis. Success could lead to a breakthrough in the fight against this deadly disease.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Pliant Therapeutics, Inc. is a late-stage biotech developing drugs for the treatment of fibrotic diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks associated with development.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pliant Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pliant Therapeutics
Pliant Therapeutics develops drugs for the treatment of fibrotic diseases. Its monthly growth is driven by the results of clinical trials of its leading drug candidates. Positive safety and efficacy data presented at medical conferences are the main driver.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of treatments for fibrotic diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its cutting-edge approach to treating pulmonary and liver fibrosis in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pliant Therapeutics is a biotech company whose stock is preoccupied with the results of clinical trials. Its monthly performance is completely disconnected from the market and driven by drug development news. The chart clearly illustrates that for such companies, trial data is more important than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pliant Therapeutics
Pliant Therapeutics, a biopharmaceutical company focused on treating fibrotic diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials of its drugs, where any event could dramatically alter the company's outlook.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Pliant Therapeutics combats fibrotic diseases such as pulmonary fibrosis. This is a complex area with a high unmet need. This chart compares market reactions to news of Pliant's developments with overall trends in the pharmaceutical sector and assesses the extent to which investors believe in its scientific approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pliant Therapeutics is a clinical-stage biotech. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that PLRX's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
PLRX - Market capitalization of the company Pliant Therapeutics
The Pliant Therapeutics chart is a financial map of the fight against fibrosis—tissue scarring. This biotech company's market cap reflects the hopes for its drugs for the treatment of pulmonary and liver fibrosis. Its dynamics are a barometer of progress in clinical trials in an area with a huge unmet medical need.
PLRX - Share of the company's market capitalization Pliant Therapeutics within the market segment - Specialized pharma
Pliant Therapeutics' stake in the specialty pharmaceuticals sector is focused on the fight against fibrosis. The company develops drugs to treat diseases associated with scar tissue formation. Its market share reflects the potential of its breakthrough approaches in this complex medical field.
Market capitalization of the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Pliant is seeking to find a cure for diseases associated with scar tissue formation.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pliant Therapeutics develops drugs to treat fibrotic diseases such as pulmonary and liver fibrosis. Its market capitalization reflects the hope of developing therapies for these debilitating conditions. The chart below shows the economic weight of companies fighting fibrosis.
Book value capitalization of the company, segment and market as a whole
PLRX - Book value capitalization of the company Pliant Therapeutics
The book value of Pliant Therapeutics, a biopharmaceutical company, is its R&D capital. The chart below shows financial resources, not manufacturing facilities. This level is an indicator of its ability to finance clinical trials of innovative drugs for fibrotic diseases.
PLRX - Share of the company's book capitalization Pliant Therapeutics within the market segment - Specialized pharma
Pliant Therapeutics is a biotech company developing therapies for fibrotic diseases. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are its high-tech laboratories.
Market segment balance sheet capitalization - Specialized pharma
Pliant Therapeutics is a clinical-stage biotech company. Its value is created in the laboratories where it develops fibrosis drugs. This is a "light" model. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Pliant Therapeutics' balance sheet represents capital focused on developing drugs to treat fibrotic diseases, such as idiopathic pulmonary fibrosis. The book value chart shows the resources devoted to combating the tissue scarring process that underlies many diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases such as pulmonary fibrosis. The company has no tangible assets. Its market capitalization is a valuation of its scientific platform and its hopes of developing the first effective treatment for these deadly diseases. The chart reflects the progress of its clinical programs.
Market to book capitalization ratio in a market segment - Specialized pharma
Pliant Therapeutics is a biopharmaceutical company developing drugs to treat fibrotic diseases. Its value is derived from its scientific platform and pipeline. The chart shows the significant premium investors are paying for the potential of its innovative treatment approaches.
Market to book capitalization ratio for the market as a whole
Pliant Therapeutics is a biotech company focused on treating fibrotic diseases. The chart shows how the market values this innovative approach to combating tissue scarring. The company's market capitalization is based on the potential of its scientific platform to develop drugs for a wide range of serious diseases, which generates a high premium for its assets.
Debts of the company, segment and market as a whole
PLRX - Company debts Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases. Being in clinical trials, the company requires significant investment. This chart shows how Pliant raises capital, including debt, to finance its lengthy and complex drug development programs.
Market segment debts - Specialized pharma
Pliant Therapeutics is a biopharmaceutical company focused on treating fibrotic diseases, a complex area with unmet medical needs. The chart shows the common financial metrics for the biotech sector, against which Pliant is raising capital to advance its innovative candidates through all stages of expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases such as pulmonary fibrosis. This is a complex area of medicine that requires long-term investment. This chart shows the company's reliance on debt to fund its expensive research, allowing us to assess its financial risks in developing a cure.
Market segment debt to market segment book capitalization - Specialized pharma
Pliant Therapeutics' development of drugs for fibrotic diseases targets conditions for which there are currently no effective therapies. This chart shows how the biotech sector funds its innovations. It allows us to assess how Pliant's financial model, operating at the forefront of science, differs from other companies and how it funds its expensive research.
Debt to book value of all companies in the market
Pliant Therapeutics fights fibrotic diseases such as pulmonary fibrosis. Developing drugs in this complex field requires persistence and significant capital. The chart shows how their debt load, required to fund years of research, compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Pliant Therapeutics
This figure for Pliant Therapeutics, a biopharmaceutical company fighting fibrosis (tissue scarring), reflects investor expectations. The company's value is determined not by current profits, but by the potential of its drugs to treat diseases for which there is currently no effective therapy. The chart is a measure of hope for a scientific breakthrough.
P/E of the market segment - Specialized pharma
This indicator represents the average valuation for the biotech sector in which Pliant Therapeutics operates. It reflects the overall level of hope and expectation in the field of fibrotic disease treatments. The chart serves as a barometer of investor confidence in the future of anti-scar drugs.
P/E of the market as a whole
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis, which causes tissue scarring. This is a complex area with unmet medical needs. This chart shows biotech sentiment. It helps understand whether the market believes in Pliant's scientific approach and how it views the company's potential in this complex but promising therapeutic area.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pliant Therapeutics
Pliant Therapeutics develops small-molecule drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company's future depends on the success of its innovative approach. This chart reflects investor expectations regarding the potential of its platform to combat tissue scarring, for which effective treatments are currently scarce.
%20P%2FE%20Pliant%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pliant-Therapeutics&v=1772612356888 "Chart of the company's future (projected) P/E Pliant Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis. Fibrosis is the process of scar tissue formation, which the company is trying to stop. The chart reflects expectations for the biotech sector, helping to understand how the market values this approach to treating severe and progressive diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772612356914 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. These are complex and difficult-to-treat conditions. This graph of overall expectations demonstrates the market's willingness to fund biotech. Investor optimism is essential to attract capital for the development of drugs for diseases with unmet medical needs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612356916 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pliant Therapeutics
Pliant Therapeutics develops treatments for fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. This chart shows the financial costs of tackling these difficult-to-treat diseases. Revenue is a long-term goal, and current metrics reflect investments in clinical trials and platform development.
Profit of companies in the market segment - Specialized pharma
LightInTheBox Holding is a global online retailer selling products directly from Chinese manufacturers. Its profitability depends on managing complex logistics and the highly competitive cross-border e-commerce market. This chart illustrates how low prices attract shoppers, but low margins and high marketing costs make achieving consistent profitability challenging.
Overall market profit
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company's success depends on the results of clinical trials in these complex areas. This is an example of how biotechnology is targeting problems where there is currently no effective treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pliant Therapeutics
Pliant Therapeutics is a biotech company focused on treating fibrotic diseases such as idiopathic pulmonary fibrosis. Its profit outlook is long-term and depends on the success of clinical trials. This chart reflects analyst expectations regarding the potential of its drugs to combat the tissue scarring process that underlies many diseases.
%20profit%20of%20the%20company%20Pliant%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pliant-Therapeutics&v=1772612356937 "Graph of future (projected) profit of the company Pliant Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company focuses on integrin inhibition. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the hopes associated with finding effective treatments for rare and severe diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772612356950 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Pliant Therapeutics develops treatments for fibrotic diseases such as liver and lung fibrosis. This is an area of unmet medical need. The corporate earnings forecasts reflected here impact the investment environment rather than demand, determining the willingness of investors and large pharmaceutical companies to invest in breakthrough therapies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612356968 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pliant Therapeutics
Pliant Therapeutics is a biotech company focused on treating fibrotic diseases such as idiopathic pulmonary fibrosis by inhibiting integrins. Although it has no sales revenue, its valuation reflects investors' faith in its innovative scientific approach to treating conditions associated with scar tissue formation.
P/S market segment - Specialized pharma
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for fibrosis, a tissue scarring process, in diseases such as idiopathic pulmonary fibrosis. This chart shows the average valuation in the sector, providing insight into the market's perception of Pliant's revenue potential.
P/S of the market as a whole
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis. The company targets the inhibition of integrins, which play a key role in fibrosis. This chart, showing average valuations, clearly demonstrates the premium investors are willing to place on the potential revenue of this breakthrough drug.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. This chart reflects investor confidence in the future success of its platform. The valuation is based on expectations for clinical trials, which could lead to the development of first-in-class drugs.
%20P%2FS%20Pliant%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pliant-Therapeutics&v=1772612357060 "The graph of the company's future (projected) P/S Pliant Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Its approach is aimed at inhibiting integrins. The chart shows how investors estimate Pliant's future sales, reflecting the high potential of its therapy for diseases with unmet medical needs.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772612357072 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Investor optimism about future earnings hinges on the search for drugs for fibrotic diseases. Pliant Therapeutics develops drugs to treat conditions that involve tissue scarring, such as idiopathic pulmonary fibrosis. Their scientific approach to this complex problem inspires hope for the development of effective therapies for these devastating diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612357083 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of fibrotic diseases. At this stage, its revenue is generated not from product sales but from upfront and milestone payments from major pharmaceutical partners. This chart illustrates the progress of its research and the attractiveness of its scientific platform.
Sales of companies in the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. This chart shows total revenue in the specialty pharmaceuticals sector. It illustrates the significant unmet need in treating diseases associated with tissue scarring, where Pliant is a pioneer.
Overall market sales
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis. Its value is determined by the potential of its lead candidates. This overall economic outlook influences overall investment appetite for risky but potentially breakthrough biotech companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pliant Therapeutics
Pliant Therapeutics develops small-molecule drugs for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis. The company's success depends on the results of clinical trials. The chart shows analysts' speculative revenue forecasts, which are betting on a breakthrough in the treatment of these severe and progressive diseases.
%20sales%20of%20the%20company%20Pliant%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pliant-Therapeutics&v=1772612357164 "Schedule of future (projected) sales of the company Pliant Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Fibrosis is a complex medical condition. This chart displays projected sales for the entire specialty pharmaceuticals segment, highlighting overall growth expectations for the market for drugs for rare and complex diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772612357227 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Pliant Therapeutics is a biopharmaceutical company developing drugs to treat fibrotic diseases. The company is in the clinical stage, and its future depends on the success of its trials. This overall economic climate impacts the availability of capital for the biotech sector, which is necessary to finance lengthy and expensive R&D programs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612357285 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases. This metric is a financial reflection of its scientific activity. It demonstrates the amount of investment in clinical trials required to bring new drugs to market and transform scientific breakthroughs into commercial products.
Market segment marginality - Specialized pharma
Pliant Therapeutics develops drugs to treat fibrotic diseases such as pulmonary and liver fibrosis. Profitability at the clinical stage is a long-term goal for the company. This metric reflects its operational structure and the efficiency with which it utilizes capital to advance its developments, compared to other specialized pharmaceutical companies.
Market marginality as a whole
Pliant Therapeutics develops small-molecule drugs for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis. Their approach targets integrin inhibition. The company's success depends on clinical trial results. This overall profitability curve doesn't affect their research activities, but it is important for raising capital from investors.
Employees in the company, segment and market as a whole
Number of employees in the company Pliant Therapeutics
Pliant Therapeutics develops drugs to treat fibrotic diseases such as pulmonary and liver fibrosis. At the clinical stage, its main asset is its scientific expertise. This chart shows how the company is expanding its team of scientists and clinicians to advance its innovative molecules through complex clinical trials.
Share of the company's employees Pliant Therapeutics within the market segment - Specialized pharma
Pliant Therapeutics develops treatments for fibrotic diseases such as idiopathic pulmonary fibrosis. This chart shows the concentration of unique scientists and clinicians in this complex field. This share reflects its leadership in the search for ways to halt the tissue scarring process.
Number of employees in the market segment - Specialized pharma
Pliant Therapeutics, Inc. is a biotech company focused on treating fibrotic diseases such as idiopathic pulmonary fibrosis. This chart shows overall occupancy in the specialty pharmaceuticals sector. It illustrates how the company is targeting complex diseases for which there is currently no effective treatment, requiring deep scientific expertise.
Number of employees in the market as a whole
Pliant Therapeutics develops drugs to treat fibrotic diseases such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis. These are complex and progressive conditions. This graph illustrates the labor market, where biotech companies targeting unsolved medical problems are creating a demand for highly specialized scientists and clinicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pliant Therapeutics (PLRX)
Pliant Therapeutics develops drugs to treat fibrotic diseases. This chart shows a classic picture for a biotech company. The high market capitalization per employee suggests that investors are evaluating the scientific platform and the potential of future drugs. The value lies in the intellectual property created by a relatively small team of scientists.
%20of%20the%20company%20Pliant%20Therapeutics%20(PLRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pliant-Therapeutics-PLRX&v=1772612357430 "Chart of market capitalization per employee (in thousands of dollars) of the company Pliant Therapeutics (PLRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Pliant Therapeutics is a biotech company focused on treating fibrotic diseases. Their core asset is a scientific platform for drug discovery. This chart shows how investors view the potential of their breakthrough technology. The high market capitalization per employee reflects the market's belief that their approach can lead to first-in-class drugs.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772612357438 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat fibrotic diseases. Its valuation is based on the potential of its scientific platform. This metric demonstrates the high value of intellectual capital in biotech, where a small team of scientists can create treatments for previously untreatable conditions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612357465 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pliant Therapeutics (PLRX)
Pliant Therapeutics is a biotech R&D company focused on treating fibrotic diseases (tissue scarring), such as pulmonary fibrosis. This is a complex field of science. This chart shows the "cost" of this research: it measures the net loss (expenses associated with clinical trials) per scientist.
%20Chart%20Pliant%20Therapeutics%20(PLRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pliant-Therapeutics-PLRX&v=1772612357474 "Company Profit Per Employee (in thousands of dollars) Chart Pliant Therapeutics (PLRX)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Pliant Therapeutics is a clinical-stage company developing a treatment for fibrosis. As with many cutting-edge biotechs, this graph is a guide to the future. Their profitability per employee is currently negative. All their value lies in their scientific platform, which, if successful, could generate enormous profitability per team member.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772612357504 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Pliant Therapeutics (PLRX) is a biotech company developing treatments for fibrotic diseases (tissue scarring), such as pulmonary fibrosis. This R&D process is complex. This chart shows the company is investing heavily in research. Earnings per employee are negative until their drugs reach the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612357518 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pliant Therapeutics (PLRX)
For Pliant Therapeutics, a company developing drugs to treat fibrotic diseases, this graph reflects progress in commercializing its research. Growth in revenue per employee will depend on the success of clinical trials and partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pliant-Therapeutics-PLRX&v=1772612357519 "Sales chart per company employee Pliant Therapeutics (PLRX)")
Sales per employee in the market segment - Specialized pharma
Pliant Therapeutics is a biopharmaceutical company developing drugs to treat fibrotic diseases (such as pulmonary fibrosis). This is R&D. This metric reflects the average revenue per employee in the segment. It helps assess how productive their research team is in this complex therapeutic area compared to other biotech companies tackling fibrosis.
Sales per employee for the market as a whole
Pliant Therapeutics (PLRX) is a clinical-stage biopharmaceutical company focused on the treatment of fibrotic diseases (tissue scarring). Currently, its staff consists primarily of scientists. This metric is pending for PLRX. It will only begin to grow if clinical trials are successful and either partner payments are received or marketing approval is obtained.
Short shares by company, segment and market as a whole
Shares shorted by company Pliant Therapeutics (PLRX)
Pliant Therapeutics develops treatments for fibrotic diseases such as pulmonary fibrosis. This is a complex area with high demand, but also a high risk of failure. This chart shows how many investors are betting that its drug candidates will fail to prove effective in halting or reversing tissue scarring.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pliant-Therapeutics-PLRX&v=1772612357558 "Short Shares Chart for the Company Pliant Therapeutics (PLRX)")
Shares shorted by market segment - Specialized pharma
Pliant Therapeutics (PLRX) is a biopharmaceutical company focused on developing treatments for fibrotic diseases (such as idiopathic pulmonary fibrosis). This chart shows the overall short position in the specialty pharmaceutical sector. It reflects the high risk associated with fibrosis treatments, an area known for numerous clinical failures.
Shares shorted by the overall market
Pliant Therapeutics (PLRX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pliant Therapeutics (PLRX)
Pliant Therapeutics (PLRX) is a biotech that attacks fibrosis (tissue scarring) in the lungs and liver. It's a highly speculative R&D bet. This chart measures the level of hype. It shows when the euphoria from trial data (overbought) or doubts about the platform (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pliant-Therapeutics-PLRX&v=1772612357650 "RSI 14 indicator chart for the company's stock Pliant Therapeutics (PLRX)")
RSI 14 Market Segment - Specialized pharma
Pliant (PLRX) is a biotech company focused on *fibrosis* (scarring). They develop *inhibitors* for the treatment of *fibrotic* diseases (lung/IPF, liver/PSC). The "Specialized Pharma" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is PLRX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Pliant Therapeutics (PLRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PLRX (Pliant Therapeutics)
Pliant Therapeutics is a biopharmaceutical company developing drugs to treat fibrosis (tissue scarring), primarily idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). This chart shows the speculative average price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PLRX-Pliant-Therapeutics&v=1772612357744 "A chart showing analyst consensus forecasts for the expected stock price. PLRX (Pliant Therapeutics)")
The difference between the consensus estimate and the actual stock price PLRX (Pliant Therapeutics)
PLRX - Pliant Therapeutics is a biotech company developing drugs to treat fibrosis (tissue scarring) in the lungs (ILF) and liver (NASH). This chart shows the gap between the market valuation and the analysts' target price. It highlights the potential experts see in their breakthrough, yet risky, clinical developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PLRX-Pliant-Therapeutics&v=1772612357765 "A chart showing the difference between the consensus forecast and the actual stock price. PLRX (Pliant Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Pliant Therapeutics (PLRX) is a biotech company developing drugs to treat fibrosis (tissue scarring) in the lungs and liver. This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe a breakthrough in the treatment of these complex, progressive diseases is possible.
Analysts' consensus forecast for the overall market share price
Pliant Therapeutics is a biotech company developing drugs to treat fibrotic diseases (tissue scarring), particularly pulmonary and liver fibrosis. This chart shows the overall risk appetite. For Pliant, operating in a complex field, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pliant Therapeutics
Pliant (PLRX) is a clinical-stage biotech focused on the Holy Grail of fibrosis (scarring). They are developing drugs (integrin inhibitors) to halt and reverse scarring in the lungs (ILF) and liver (MASH). This chart represents their R&D bet. Its valuation represents the market's belief that they can crack this incredibly complex yet enormous medical problem.
AKIMA Market Segment Index - Specialized pharma
Pliant Therapeutics (PLRX) specializes in the treatment of fibrotic diseases, developing drugs that inhibit the integration of proteins that cause tissue scarring (for example, in the lungs). This chart shows the average index for the pharmaceutical sector. It helps investors assess how Pliant's scientific approach compares to the industry average.
The AKIM Index for the overall market
Pliant Therapeutics is a biotech company specializing in the treatment of fibrotic diseases (lung and liver) through integrin inhibition. This chart, reflecting the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this promising research platform in the field of fibrosis.
